United States: Electronic Drug Product Listing Errors Can Result In FDA Warning Letter

Last Updated: July 3 2017
Article by Ann M. Begley, Jacqueline R. Berman and Heather A. Dorsey

FDA Warning Letters focus on inaccurate drug product listings.

Over the last year, the US Food and Drug Administration (FDA or Agency) has increased its enforcement efforts concerning drug product listing requirements, resulting in a number of Warning Letters for what appear to be simple errors in electronic submissions of drug product listings.

The Federal Food, Drug and Cosmetic Act (FFDCA) and FDA's implementing regulations require the listing of all commercially distributed drugs (including active pharmaceutical ingredients).1 In August 2016, FDA finally completed its rulemaking to adopt the 2007 amendment to the FFDCA that requires all drug establishment registration and drug product listing information to be submitted to FDA electronically in the absence of an Agency waiver.2

While FDA has required electronic submission of this information via the electronic drug registration and listing service (eDRLS) for many years, enforcement activity for alleged violations of the listing requirements is fairly recent. Since March 2016, the Agency has issued five Warning Letters based solely on listing violations, two of which were issued in the last month.3 For example, FDA issued Warning Letters for the following submission errors:

  • Failure to update drug listing files to reflect discontinuance of drug products
  • Missing active ingredient and incorrect information
  • Missing copy of the product label
  • Incorrect spelling of the active ingredient
  • Incorrect application number referenced
  • Incorrect proprietary name included in the listing
  • Incorrect quantity for the package size
  • Incorrect strength of active ingredient
  • Failure to include the drug product's Drug Enforcement Agency (DEA) schedule4

In all cases, FDA expressed concern that incorrect drug product listings are accessible to the public, including consumers. In most cases, asserting the need to "protect and promote the public health" by "maintain[ing] a correct and accurate database," and citing misbranding and drug product listing violations under the FFDCA, the Agency immediately removed only the incorrect listings from FDA's National Drug Code (NDC) Directory such that they would not be publicly viewable.5 In one case, however, FDA did not limit removal to just those listings that were incorrect—instead, stating that "FDA's Drug Registration and Listing Staff does not have sufficient resources to check each of [the] drug listing files before the data is published," the Agency refused to make any of the firm's listing files public.6

In addition to mandating correction of the inaccurate information in the drug product listings, FDA required each Warning Letter recipient to provide a plan to prevent a recurrence of the violations.7 In the case of the firm where FDA refused to make any of the firm's listings public, the Agency required, at a minimum, that the response include the following:

  • How the firm reviewed, or plans to review, all current drug listings to identify those listings that need to be updated
  • How the firm corrected, or plans to correct, the identified errors (e.g., submit corrected Structured Product Labeling files for existing listings, delist NDCs no longer in use by submitting end marketing dates and changing marketing status to complete)
  • The plan or process the firm has implemented, or plans to implement, in order to prevent the recurrence of the violations8

Key Takeaways

While FDA occasionally cites noncompliance with the drug listing requirements in its enforcement letters, such observations frequently accompany other, more significant alleged regulatory violations. In these instances, however, the listing violations were the sole focus of FDA's enforcement letters. Moreover, based on the text of the enforcement letters, in some cases, the FDA Warning Letter may have been the first time that the Agency notified the recipient of an issue with its drug listings. Many of the cited violations likely were administrative or clerical oversights that occurred when entering the drug information into the eDRLS.

While listing drugs is perceived as merely an administrative task, failure to list drug products or incorrectly listing products is a violation of the FFDCA, as the Warning Letters reflect. Failure to fulfill listing obligations misbrands the applicable product under the FFDCA,9 and the FFDCA further prohibits the introduction of misbranded products into interstate commerce.10

Taken together, this round of Warning Letters indicates that FDA may be more apt to take public enforcement action based solely on a company's failure to properly list drug products, even in the absence of any other violations, rather than sending private communications regarding errors through the eDRLS staff. The immediate removal of a product from FDA's NDC Directory raises questions about ongoing distribution of the product pending FDA's acceptance of the corrective measures. This situation is more complicated for imported drug products if they are subject to this type of enforcement action, as they may be refused entry into the United States until FDA accepts the corrective action.11

It would appear that FDA is sending a public message to regulated firms regarding the importance of accurate and completed drug product listing submissions. As a result, firms should refamiliarize themselves with FDA's listing requirements, consider reviewing prior electronic drug product listing submissions for accuracy and compliance with FDA regulations, and assess the need for an internal procedure to ensure current listings are appropriately updated and new listings are accurate and complete before submission.

Footnotes

1 FFDCA § 510(j); 21 C.F.R. Part 207, Subpart D.

2 Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs, 81 Fed. Reg. 60169 (Aug. 31, 2016); Food and Drug Administration Amendments Act of 2007, Pub. L. 110-85 (2007).

3 See US Food & Drug Admin., Warning Letter to A-S Medication Solutions (June 5, 2017); US Food & Drug Admin., Warning Letter to Prestige Brand Holdings (June 1, 2017); US Food & Drug Admin., Warning Letter to Exact-Rx (Apr. 19, 2017); US Food & Drug Admin., Warning Letter to Targeted Medical Pharma, Inc., dba Physician Therapeutics (Oct. 6, 2016); US Food & Drug Admin., Warning Letter to Pharmaceutical Associates (Mar. 23, 2016).

4 See supra note 3.

5 See supra note 3.

6 US Food & Drug Admin., Warning Letter to A-S Medication Solutions (June 5, 2017).

7 See supra note 3.

8 See supra note 6.

9 FFDCA § 502(o).

10 FFDCA §§ 301(a), 301(p).

11 US Food & Drug Admin., Importation of Drugs Outline (Sept. 7, 2012).

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions